Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016

  • ID: 3821617
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • MedImmune, LLC
  • MORE
Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016

Summary

‘Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016’, provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targeted pipeline therapeutics.

The report provides comprehensive information on the Angiopoietin 2 (Ang 2 or ANGPT2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Angiopoietin 2 (Ang 2 or ANGPT2)
- The report reviews Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Angiopoietin 2 (Ang 2 or ANGPT2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Angiopoietin 2 (Ang 2 or ANGPT2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • MedImmune, LLC
  • MORE
List of Figures

Introduction

Report Coverage

Angiopoietin 2 (Ang 2 or ANGPT2) Overview

Therapeutics Development

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Stage of Development

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Therapy Area

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Indication

Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Companies

Angiopoietin 2 (Ang 2 or ANGPT2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Angiopoietin 2 (Ang 2 or ANGPT2) - Companies Involved in Therapeutics Development

Amgen Inc.

AnGes MG, Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

MedImmune, LLC

Regeneron Pharmaceuticals, Inc.

RXi Pharmaceuticals Corporation

Silence Therapeutics Plc

Synergys Biotherapeutics, Inc.

Angiopoietin 2 (Ang 2 or ANGPT2) - Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-30/5C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anti-Angiopoietin-1/2 Monoclonal Antibody - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit Angiopoietin-2 for Retinal Disease and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atu-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-836880 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3127804 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3617 + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Angiopoietin 2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trebananib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanucizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Angiopoietin 2 (Ang 2 or ANGPT2) - Dormant Projects

Angiopoietin 2 (Ang 2 or ANGPT2) - Discontinued Products

Angiopoietin 2 (Ang 2 or ANGPT2) - Featured News & Press Releases

Nov 04, 2014: Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis

Jun 20, 2014: University of Arizona Cancer Center at St. Joseph’s researcher reports on response of a new treatment for ovarian cancer

Jun 12, 2013: Amgen's Phase III Trial Of Trebananib Meets Primary Endpoint In Recurrent Ovarian Cancer

Nov 28, 2012: CNIO Announces Initiation Of Phase I Clinical Trial Of New Anti-tumour Drug RO5520985

Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics

Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan

Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan

Oct 09, 2010: Amgen Announces Phase II Trial Results Of AMG 386 In Patients With Recurrent Ovarian Cancer

Jun 06, 2010: Amgen's AMG 386 Demonstrates Promising Antitumor Activity In Patients With Recurrent Ovarian Cancer

Apr 13, 2008: Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules AMG 386 Suggests Biologic Activity Across Tumor Types

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Amgen Inc., H2 2016

Pipeline by AnGes MG, Inc., H2 2016

Pipeline by Boehringer Ingelheim GmbH, H2 2016

Pipeline by Eli Lilly and Company, H2 2016

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Pipeline by MedImmune, LLC, H2 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016

Pipeline by RXi Pharmaceuticals Corporation, H2 2016

Pipeline by Silence Therapeutics Plc, H2 2016

Pipeline by Synergys Biotherapeutics, Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Discontinued Products, H2 2016 53List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Amgen Inc.
AnGes MG, Inc.
Boehringer Ingelheim GmbH
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
MedImmune, LLC
Regeneron Pharmaceuticals, Inc.
RXi Pharmaceuticals Corporation
Silence Therapeutics Plc
Synergys Biotherapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll